Clinical trials: Hep A
Chronic Disease, Hepatitis C
Evaluating a Telehealth Treatment for Veterans With Hepatitis C and PTSD
The main objective of this proposal is to develop and test the efficacy of two interventions (a telehealth and face-to-face intervention) designed to improve quality of life, self-care, motivation to engage in healthcare, and…
- Conditions
- Chronic Disease, Hepatitis C, Stress Disorders, Post-Traumatic
- Trial name
- NCT00333710
- Testing
- Individual psychotherapy, Telehealth Intervention
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- US Department of Veterans Affairs
Hepatitis C
Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults
This study is a Phase I open label drug interaction study to evaluate the effect of omeprazole and ritonavir on GSK2336805.
- Trial name
- NCT01458054
- Testing
- Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose), Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C, HIV Infections
Leukapheresis for Research on HCV-Coinfected Patients
This study will collect quantities of white blood cells from patients infected with the hepatitis C virus (HCV) for research on the interactions between HCV and the human immunodeficiency virus (HIV) in people infected with both…
- Trial name
- NCT00076427
- Where
- 4 sites in United States
- Volunteers
- 327 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B
A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to GSK Biologicals Adjuvanted Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Have Not Been Exposed to Hepatitis B.
The pre-dialysis, peritoneal dialysis and haemodialysis patients would benefit from an improved hepatitis B vaccine, which will elicit stronger and faster cellular and humoral immune responses after the primary vaccination course.
- Trial name
- NCT00291941
- Testing
- Henogen HBV vaccine, FENDRIX
- Where
- 24 sites in Belgium, Czechia and 1 more
- Volunteers
- 300 people
- Sponsor
- Henogen
Pediatric Immuno-Tolerant Chronic Hepatitis B
A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase
This randomized, controlled, parallel group, open-label multicenter study will evaluate the efficacy and safety of a combination of pegylated interferon alfa-2A (Pegasys) plus lamivudine or entecavir compared with an untreated…
- Trial name
- NCT02263079
- Testing
- Entecavir, Lamivudine, Pegylated Interferon Alfa-2A
- Where
- 25 sites in United States, Australia and 10 more
- Volunteers
- 62 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B, Hepatitis, Viral, Human
Hepatitis B Vaccine Clinical Trial
To determine the efficacy of a hepatitis vaccine in preventing hepatitis B.
- Conditions
- Hepatitis B, Hepatitis, Viral, Human, Liver Diseases
- Trial name
- NCT00000583
- Testing
- hepatitis B vaccines
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hepatitis C
DBS TaT in Peer-assisted Telemedicine for Hepatitis C
The purpose of this study is to compare the rate of treatment initiation achieved by peer-assisted telemedicine contingent on phlebotomy (usual care) versus that achieved with a new protocol, called Dried Blood Spot Test and…
- Trial name
- NCT06409169
- Testing
- DBS TaT, Usual Care
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Oregon Health and Science University
Hepatitis C, Chronic
The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study
Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) offers a cure to those with chronic HCV infection. For marginalized communities, linkage to care services often aren't enough to overcome barriers to accessing the…
- Trial name
- NOW (NCT03987503)
- Testing
- Epclusa (SOF/VEL), Standard of care, Fibroscan® 430 Mini Plus
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Hepatitis C, Chronic
VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo
The purpose of this study is to provide access to telaprevir for patients from the control group in the C216 study, who failed treatment for virologic reasons.
- Trial name
- NCT01054573
- Testing
- Telaprevir, pegylated interferon (Peg-IFN) alfa-2a, ribavirin (RBV)
- Where
- 48 sites in United States, Australia and 13 more
- Volunteers
- 90 people
- Sponsor
- Janssen Infectious Diseases BVBA
Hepatitis B, HIV
Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV .
Hepatitis B virus infection is a common occurrence among patients with HIV. Effective vaccines are available, but there's some uncertainty regarding specific dosages, specially among those who have not responded to an initial…
- Trial name
- CORE-HIV (NCT02003703)
- Testing
- Recombinant Hepatitis B Virus Vaccine
- Where
- Chile
- Volunteers
- 107 people
- Sponsor
- Universidad de Valparaiso
Hepatitis C
A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study
A follow-up study to assess resistance and durability of response to 3 experimental drugs ABT-450/r, ABT-267, and ABT-333 in participants who have participated in AbbVie Phase 2 or 3 clinical studies with these agents for the…
- Trial name
- NCT01773070
- Testing
- ABT-450/ritonavir, ABT-333, ABT-267
- Volunteers
- 478 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Hepatitis C
Virological Response Study of the HCV Vaccine IC41
The objective is to investigate the virological (HCV-RNA) responses following biweekly immunization with IC41. Treatment phase 14 weeks, total study duration including follow-up period 38 weeks.
- Trial name
- NCT00601770
- Testing
- IC41
- Where
- 8 sites in Germany, Poland and 1 more
- Volunteers
- 71 people
- Sponsor
- Valneva Austria GmbH
Hepatitis C
Hepatitis C Antiviral Resistance in African-Americans
This study is designed to test the hypothesis that African-Americans respond less well to combination pegylated interferon and ribavirin therapy than Caucasian-Americans who have chronic hepatitis C genotype 1 and who were not…
- Trial name
- NCT00038974
- Testing
- peginterferon alfa-2a, Ribavirin
- Where
- 8 sites in United States
- Volunteers
- 401 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis B Virus, Liver Transplant
To Evaluate the Efficacy and Safety of Tenofovir Alafenamide Conversion in Liver Transplant Patients
This clinical trial aims to confirm the efficacy and safety of Vemlia® tablets (Tenofovir alafenamide) in liver transplant patients with hepatitis B, focusing on their effects on renal function.
- Conditions
- Hepatitis B Virus, Liver Transplant, Renal Insufficiency
- Trial name
- NCT06589518
- Testing
- Tenofovir Alafenamide Citrate
- Volunteers
- 108 people
- Sponsor
- Jongman Kim
Chronic Hepatitis C Genotype-1 Relapse
Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients
This is a study designed to identify a dose of NIM811 that has a good safety profile, is well tolerated when co-administered with SOC, and provides a clinically meaningful effect in viral load reduction compared to SOC alone.
- Trial name
- NCT00983060
- Testing
- NIM811
- Where
- 16 sites in United States, Australia and 5 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Hepatitis C
High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4
Optimal ribavirin dosages are essential in achieving SVR (sustained virological response). Several studies have shown higher SVR rates in patients receiving higher doses of ribavirin.
- Trial name
- VIRID (NCT00662220)
- Testing
- ribavirin
- Where
- 27 sites in Netherlands
- Volunteers
- 110 people
- Sponsor
- Foundation for Liver Research
Hepatitis B
A Study to Characterise Immune Responses Following Immunisations With "Fendrix" or "Engerix B" Hepatitis B Vaccines
The purpose of this study is to generate an exploratory training set of data and to identify predictive biomarkers (a measurable biological response that predicts something) of innate and adaptive responses to immunisation of two…
- Trial name
- NCT02032160
- Testing
- Engerix B IM injection - 20ug, Fendrix IM injection - 20ug
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Surrey
Hepatitis B, Chronic
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B
This multicenter, prospective, observational study will evaluate the efficacy and safety of Pegasys (peginterferon alfa-2a) in routine clinical practice in patients with HBeAg-positive or HBeAg-negative chronic hepatitis B.
- Trial name
- NCT01734018
- Where
- 2 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis b
Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Chronic Hepatitis b
This study is to investigate the clinical efficacy and safety of three types of nucleotide/nucleoside analogues in treatment of chronic hepatitis b
- Trial name
- NCT04195074
- Testing
- Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Alcoholic Hepatitis
PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis
Only patients suffering from a severe form of alcoholic hepatitis (Maddrey's discriminant function greater than 32) require medical treatment.
- Trial name
- PROCORNAC (NCT06956482)
- Testing
- N-Acetylcysteine (NAC) Treatment, Prednisolone, Prednisolone 10mg
- Where
- France
- Volunteers
- 477 people
- Sponsor
- University Hospital, Lille
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.